Insmed (INSM) Competitors $96.14 -0.81 (-0.84%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$97.28 +1.14 (+1.19%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. REGN, ALNY, ARGX, BNTX, RPRX, BIIB, ILMN, GMAB, INCY, and EXELShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), argenex (ARGX), BioNTech (BNTX), Royalty Pharma (RPRX), Biogen (BIIB), Illumina (ILMN), Genmab A/S (GMAB), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "med - biomed/gene" industry. Insmed vs. Its Competitors Regeneron Pharmaceuticals Alnylam Pharmaceuticals argenex BioNTech Royalty Pharma Biogen Illumina Genmab A/S Incyte Exelixis Regeneron Pharmaceuticals (NASDAQ:REGN) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Do institutionals and insiders hold more shares of REGN or INSM? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is REGN or INSM more profitable? Regeneron Pharmaceuticals has a net margin of 31.94% compared to Insmed's net margin of -265.93%. Regeneron Pharmaceuticals' return on equity of 15.27% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.94% 15.27% 11.93% Insmed -265.93%-446.98%-52.70% Do analysts rate REGN or INSM? Regeneron Pharmaceuticals currently has a consensus target price of $813.57, suggesting a potential upside of 48.53%. Insmed has a consensus target price of $108.07, suggesting a potential upside of 12.41%. Given Regeneron Pharmaceuticals' higher possible upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.80Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor REGN or INSM? In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than Insmed. MarketBeat recorded 35 mentions for Regeneron Pharmaceuticals and 8 mentions for Insmed. Insmed's average media sentiment score of 1.13 beat Regeneron Pharmaceuticals' score of 0.95 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 19 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, REGN or INSM? Regeneron Pharmaceuticals has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Which has preferable valuation & earnings, REGN or INSM? Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.20B4.16$4.41B$39.2813.94Insmed$363.71M50.15-$913.77M-$5.95-16.16 SummaryRegeneron Pharmaceuticals beats Insmed on 12 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.39B$2.87B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.04%P/E Ratio-16.1620.8027.0020.11Price / Sales50.15286.27429.45119.84Price / CashN/A41.1936.8257.86Price / Book60.097.487.985.56Net Income-$913.77M-$55.04M$3.16B$248.40M7 Day Performance-2.14%2.44%2.38%4.67%1 Month Performance36.02%1.90%2.17%6.64%1 Year Performance36.82%4.35%33.80%21.31% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.5531 of 5 stars$96.14-0.8%$108.07+12.4%+37.2%$18.39B$363.71M-16.161,271Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.9355 of 5 stars$525.00+0.8%$813.57+55.0%-47.9%$56.68B$14.20B13.3711,900Analyst RevisionALNYAlnylam Pharmaceuticals4.1176 of 5 stars$326.09+1.0%$340.00+4.3%+24.5%$42.52B$2.35B-156.022,000Positive NewsAnalyst ForecastARGXargenex4.3888 of 5 stars$551.22-1.6%$729.93+32.4%+23.4%$33.66B$2.58B34.00650Analyst UpgradeHigh Trading VolumeBNTXBioNTech1.4391 of 5 stars$106.47-0.2%$137.86+29.5%+38.7%$25.59B$2.98B-31.313,080RPRXRoyalty Pharma4.8864 of 5 stars$36.03+0.4%$47.33+31.4%+38.1%$20.26B$2.26B19.4880Positive NewsBIIBBiogen4.9571 of 5 stars$125.59-0.4%$188.48+50.1%-41.0%$18.40B$9.68B12.407,605ILMNIllumina4.8726 of 5 stars$95.41+0.7%$127.39+33.5%-7.9%$15.10B$4.37B-15.729,030Positive NewsAnalyst ForecastGMABGenmab A/S4.0088 of 5 stars$20.66+0.8%$37.60+82.0%-16.6%$13.25B$3.12B11.742,682Analyst ForecastINCYIncyte4.7635 of 5 stars$68.10-0.4%$74.53+9.4%+16.3%$13.18B$4.24B212.822,617Trending NewsInsider TradeEXELExelixis4.7059 of 5 stars$44.08+0.9%$43.56-1.2%+97.0%$12.02B$2.17B20.041,147Trending NewsAnalyst ForecastOptions Volume Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors argenex Competitors BioNTech Competitors Royalty Pharma Competitors Biogen Competitors Illumina Competitors Genmab A/S Competitors Incyte Competitors Exelixis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INSM Stock Alerts